RecruitingNon-cystic Fibrosis BronchiectasisChronic Obstructive Pulmonary Disease

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

Eligible age

18+ yrs

Accepts

All genders

Locations

6 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

Sponsor: Genentech, Inc.

✓ Percent predicted FEV1 ≥ 40% by spirometry during screening
✓ Ability to demonstrate correct use of the smart DPI at screening, in the investigator's judgment
✓ On a stable treatment regimen for muco-obstructive diseases for ≥ 28 days prior to initiation of study treatment and willingness to remain on the stable treatment regimen through completion of study
✓ Stable disease for ≥ 28 days prior to screening and through to initiation of study treatment
✓ Additional Inclusion Criteria for Participants in Part B
✓ Chronic sputum production of ≥1 teaspoon per day as reported in the sputum volume item
✓ Ability to produce a sputum sample that is suitable for central laboratory determination of mucus percent solids and sialic acid concentration exploratory biomarker research, and biomarker assay development
✓ Availability of a representative blood sample for exploratory biomarker research and biomarker assay development

✕ Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the timeframe in which contraception is required
✕ Known significant bronchodilator response of \>10% predicted change in FEV1 or FVC, in the investigator's judgment
✕ Use of any prohibited medications
✕ Acute respiratory infection within 28 days of screening
✕ Significant hemoptysis greater than 60 milliliter (mL) within 3 months prior to screening
✕ Known immunodeficiency that, in the investigator's judgment, is clinically significant and places the individual at a substantially elevated risk for opportunistic infections.
✕ Known substance abuse, in the investigator's judgment, within 12 months prior to screening
✕ Poor peripheral venous access

Birmingham · Vestavia Hills

Palo Alto

Kansas City

Chapel Hill

Pittsburgh

Boerne

Source: ClinicalTrials.gov · NCT06603246 · last updated 2026-06-04